Cite
HARVARD Citation
Cohen, J. et al. (2020). Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Cancer. 126 (6), pp. 1235-1242. [Online].